Breaking Finance News

Argos Therapeutics Inc (NASDAQ:ARGS) has been downgraded to Hold in a report by Zacks Investment Research today.

Yesterday Argos Therapeutics Inc (NASDAQ:ARGS) traded 0.82% higher at $4.89. The company’s 50-day moving average is $4.87 and its 200-day moving average is $5.92. The last closing price is down -17.46% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 102,114 shares of ARGS traded, down from an avg. volume of 226,809

Zacks Investment Research has downgraded Argos Therapeutics Inc (NASDAQ:ARGS) to Hold in a report released on Tuesday October 11, 2016.

Previously on Monday August 15, 2016, Zacks Investment Research reported on Argos Therapeutics Inc (NASDAQ:ARGS) increased the target price from $0.00 to $5.00. At the time, this indicated a possible upside of 0.16%.

Recent Performance Chart

Argos Therapeutics Inc (NASDAQ:ARGS)

Argos Therapeutics Inc has 52 week low of $1.61 and a 52 week high of $13.97 and has a market cap of $0.

In addition to Zacks Investment Research reporting its target price, a total of 6 firms have reported on the stock. The consensus target price is $11.50 with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Argos Therapeutics Inc (NASDAQ:ARGS)

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.